Francesca Khani

Integrated signatures define mutational processes in prostate cancer

Andreas J. Gruber, André Vidas Olsen, Bárbara Hernando, Kevin C. L. Cheng et autres

. Here we dissect the mutational processes shaping the genomes of 959 donors from the Pan Prostate Cancer Group and assess their clinical relevance. By integrating de novo extracted single-base substitution, insertion-deletion and copy-number signatures with six novel complex structural variant signatures, …

de, dk, es, ca, gb, fi, us, fr, au, Afrique du Sud, be (code pays fourni par la source)

Recurrent mechanisms of biallelic epigenetic inactivation reveal new putative tumour suppressor genes in prostate cancer

Daria Kiriy, Francesco Favero, Clarissa Gerhäuser, Jessica Heilmann et autres

The inactivation of tumour suppressor genes is a key step in cancer development, and is usually achieved by homozygous loss. In prostate cancer, however, large genomic regions are often hemizygously lost, which complicates the identification of putative tumour suppressors in these regions. …

dk, de, be, es, ca, fi, gb, us, fr, au, Afrique du Sud (code pays fourni par la source)

Combination of Radiation Therapy and Irreversible Electroporation for Intermediate-Risk Prostate Cancer (RTIRE): A Phase 1 Trial

Timothy D. Mcclure, Shu Wang, Karla V. Ballman, Marshall Diven et autres

Treatment of participants with intermediate-risk prostate cancer with focal irreversible electroporation and radiation therapy was technically feasible and showed acceptable patient-reported outcomes and no severe adverse events over 1 year.

us (code pays fourni par la source)

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

Jennie N. Jeyapalan, Veronika M. Metzler, Simone de Brot, Corinne L. Woodcock et autres

Treatment resistance has become a major challenge in cancer research, particularly for patients with advanced castration resistant prostate cancer (CRPC) where no curative therapies are available. Epigenetic alterations play a significant role in cancer progression. In prostate cancer (PCa), where androgen receptor …

gb, us, ch, Nigéria, se (code pays fourni par la source)

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer.

Jennie N. Jeyapalan, Veronika M. Metzler, Simone de Brot, Corinne L. Woodcock et autres

Treatment resistance has become a major challenge in cancer research, particularly for patients with advanced castration resistant prostate cancer (CRPC) where no curative therapies are available. Epigenetic alterations play a significant role in cancer progression. In prostate cancer (PCa), where androgen receptor …

de (code pays fourni par la source)

Imaging meets genomics in treatment-naïve prostate cancer: SUVmax on prostate-specific membrane antigen (PSMA) PET as a biomarker of genomic classifier risk.

Sophia Coraci, Valentina Marulanda Corzo, Christopher E. Barbieri, Brian D. Robinson et autres

267 Background: Genomic Classifiers (GC) are increasingly used at the initial staging of prostate cancer to refine prognosis and guide treatment planning. The Decipher genomic classifier is a validated prognostic tool in prostate cancer, that predicts the risk of metastasis and prostate …

us (code pays fourni par la source)

796 Differential Expression of ASCL1, NEUROD1, and YAP1 in Neuroendocrine Prostate Cancer (NEPC) Suggests Potential Molecular Subtypes

Jordan H. Driskill, Jessica Mora, Eda Nur Kozan, Maneeza Bilal et autres

us (code pays fourni par la source)

839 Histologic Features “Suspicious for Extraprostatic Extension” on Core Biopsy Are Strongly Correlated with Extraprostatic Extension at Radical Prostatectomy

Khalia Moreau, Verónica Ochoa Cholán, Jordan H. Driskill, Jiangling Tu et autres

us (code pays fourni par la source)

797 RB1 Protein Loss is Not Required for All Castration-Resistant and Neuroendocrine Histological Variants of Prostate Cancer

Jordan H. Driskill, Eda Nur Kozan, Jessica Mora, Derek van Pel et autres

us, de (code pays fourni par la source)

Author response for "KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer"

Jennie N. Jeyapalan, Veronika M. Metzler, Simone de Brot, Corinne L. Woodcock et autres

Abstract A069: Radiotherapy remodels the tumor microenvironment via a TREM2-associated macrophage program that can be therapeutically targeted with TREM2 blockade

Janny A. Villa-Pulgarín, Un In Chan, Jiansheng Wu, Fabio Socciarelli et autres

Abstract The prostate cancer (PCa) tumor microenvironment (TME) is enriched in myeloid cells that drive progression and therapy resistance. Tumor-associated macrophages (TAM) can promote tumor growth by suppressing antitumor immunity. We have previously shown that stereotactic body radiotherapy (SBRT) induces inflammatory remodeling …

us (code pays fourni par la source)

Abstract PR027: Spatial heterogeneity atlas of prostate cancer evolution (SHAPE): Spatial and genomic landscapes of advanced prostate cancer with and without Lu-PSMA therapy

Martin K. Bakht, Jacob Egelberg, Yasutaka Yamada, Louise Clark et autres

Abstract Background: PSMA expression is heterogeneous across advanced prostate cancer, limiting the durability of PSMA-radioligand therapy (RLT). To characterize tumor heterogeneity and identify determinants of RLT resistance, we established the SHAPE cohort (Spatial Heterogeneity Atlas of Prostate Cancer Evolution). SHAPE is a …

us (code pays fourni par la source)